Our Pricing

Wegovy Discount Code UK: How to Access Lower-Cost Semaglutide

Published on: June 03, 2026

Searching for a wegovy discount code uk to reduce treatment costs? At Cured Pharmacy, new patients can access Wegovy from £79.00 with code WEIGHTLOSSNEW — that's £20 off first order using code WEIGHTLOSSNEW

How the Wegovy Discount Code Works at Cured Pharmacy

When you apply discount code WEIGHTLOSSNEW during checkout, you'll receive £20 off first order using code WEIGHTLOSSNEWWegovy prescription at Cured Pharmacy. This brings the starting price to £79.00 for eligible doses, with no hidden fees or subscription commitments. The discount applies automatically once you've completed your clinical assessment with one of our UK prescribers.

Unlike promotional offers that expire after one month, our pricing structure is designed to remain competitive throughout your weight management journey. All Wegovy prescriptions dispensed by Cured Pharmacy are genuine UK-licensed medicines sourced directly through regulated pharmaceutical supply chains, verified by our superintendent pharmacist Tarun Kumar (GPhC 2233073).

Understanding Wegovy Semaglutide: Clinical Evidence and Mechanism

Wegovy contains semaglutide, a GLP-1 receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities [1]. Semaglutide mimics the action of glucagon-like peptide-1, a hormone that regulates appetite and food intake by acting on receptors in the brain.

The landmark STEP 1 trial demonstrated that patients using semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% in the placebo group [1]. In STEP 2, which specifically enrolled participants with type 2 diabetes, semaglutide produced an average 9.6% weight loss alongside improved glycaemic control [2].

Clinical response varies between individuals, and your UK prescriber will monitor your progress throughout treatment. Wegovy is administered as a once-weekly subcutaneous injection, with dosing gradually increased over 16-20 weeks to minimise gastrointestinal side effects and improve tolerability.

Who Can Use Wegovy in the UK?

Wegovy is licensed for adults with a BMI ≥30 kg/m², or ≥27 kg/m² with at least one weight-related comorbidity such as hypertension, type 2 diabetes, or obstructive sleep apnoea. NICE guidelines recommend GLP-1 receptor agonists as part of a comprehensive weight management programme that includes dietary modification and increased physical activity [3].

During your free consultation at Cured Pharmacy, our UK prescribers will assess your medical history, current medications, and weight management goals to determine if Wegovy is clinically appropriate. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and pregnancy or breastfeeding.

Wegovy Pricing Transparency: What You'll Actually Pay

At Cured Pharmacy, Wegovy pricing starts from £79.00 per pen, with the final cost determined by your prescribed dose. We display all prices upfront before you begin your consultation — no surprises at checkout. This transparent approach contrasts with services that only reveal pricing after lengthy questionnaires.

Your prescribed dose depends on your treatment phase. Wegovy follows a five-step dose escalation schedule: 0.25mg for weeks 1-4, 0.5mg for weeks 5-8, 1mg for weeks 9-12, 1.7mg for weeks 13-16, and the maintenance dose of 2.4mg from week 17 onwards. Each pen contains four weekly doses at the lower strengths, or a single monthly dose at the 2.4mg maintenance level.

All prices include the medication, UK prescriber assessment, and discreet delivery to your chosen address. There are no membership fees, and you're never locked into automatic refills. You control when and if you reorder, with the same clinical oversight for every prescription.

Comparing Semaglutide Options: Wegovy vs Ozempic

Both Wegovy and Ozempic contain semaglutide, but they're licensed for different indications in the UK. Ozempic is specifically licensed for type 2 diabetes management at doses up to 1mg weekly, whilst Wegovy is licensed for chronic weight management at the higher 2.4mg maintenance dose [4].

The STEP trials used the 2.4mg dose that's now available as Wegovy, demonstrating significantly greater weight loss than the lower doses used in diabetes treatment. Using Ozempic off-label for weight loss means you're receiving a sub-therapeutic dose for that indication, which may explain why some patients report less dramatic results.

UK prescribers must follow MHRA licensing when prescribing. At Cured Pharmacy, if your primary goal is weight management and you meet the BMI criteria, our clinical team will assess you for Wegovy rather than off-label alternatives. This ensures you receive the evidence-based dose studied in weight loss trials.

Alternative GLP-1 Weight Loss Treatments

Beyond semaglutide, other GLP-1 receptor agonists are available through UK pharmacies for weight management. Each has distinct dosing schedules, efficacy profiles, and cost considerations. Your prescriber will discuss which option aligns best with your clinical needs, lifestyle, and budget.

Newer dual-action medications that target both GLP-1 and GIP receptors have shown even greater weight loss in clinical trials, though they typically come at higher price points. The choice between different treatments should be guided by clinical evidence, tolerability, and your individual response rather than cost alone.

Starting Your Wegovy Treatment: The Clinical Process

Beginning Wegovy through Cured Pharmacy takes under three minutes. You'll complete a confidential medical questionnaire covering your weight history, current health conditions, medications, and previous weight loss attempts. This information is reviewed by a UK-registered prescriber who determines if Wegovy is clinically appropriate for you.

If approved, your prescription is sent electronically to our dispensing team. We source all Wegovy pens from licensed UK wholesalers — never grey market imports. Each pen arrives in discreet, unmarked packaging with full patient information leaflets and injection guidance. Delivery typically occurs within 2-3 working days to addresses across England, Scotland, Wales, and Northern Ireland.

Your first injection uses the 0.25mg starting dose, administered once weekly on the same day each week. You'll gradually increase the dose every four weeks as your body adapts. Our clinical team remains available throughout your treatment for questions about side effects, dose adjustments, or general support. Follow-up assessments occur before each prescription renewal to monitor your progress and safety.

Managing Side Effects and Maximising Results with Wegovy

The most common side effects of Wegovy are gastrointestinal: nausea, diarrhoea, vomiting, and constipation [1]. These typically occur during dose escalation phases and diminish as your body adapts to each new strength. Eating smaller, more frequent meals and avoiding high-fat foods can help minimise discomfort during the first weeks of treatment.

In clinical trials, approximately 5-7% of participants discontinued Wegovy due to gastrointestinal side effects [1]. If you experience persistent nausea or vomiting that prevents adequate hydration, contact your prescriber immediately. They may recommend remaining at your current dose longer before escalating, or adjusting the timing of your injection relative to meals.

Weight loss with Wegovy is most effective when combined with lifestyle modifications. The STEP trials enrolled participants who also received counselling on reduced-calorie diets and increased physical activity [1][2]. Think of semaglutide as a tool that makes sustainable behaviour change easier by reducing hunger and food preoccupation, rather than a standalone solution. Regular monitoring of your progress helps identify what dietary and activity patterns work best for your individual response.

Long-Term Weight Maintenance on Wegovy

The STEP 4 trial examined what happens when patients stop Wegovy after achieving weight loss. Participants who discontinued treatment regained approximately two-thirds of their lost weight over the following year, whilst those who continued semaglutide maintained their weight loss [5]. This suggests that for many people, ongoing treatment may be necessary for sustained results.

UK prescribers typically recommend continuing Wegovy as long as you're achieving clinical benefit (≥5% weight loss after 3-6 months) and tolerating the medication well. Regular reviews assess whether continued treatment remains appropriate based on your weight trajectory, side effects, and overall health improvements. Some patients successfully transition to lower maintenance doses after reaching their goal weight, though this should always be done under prescriber guidance.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., et al. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
4. Medicines and Healthcare products Regulatory Agency. (2023). Wegovy 2.4mg solution for injection in pre-filled pen: Summary of Product Characteristics. https://products.mhra.gov.uk/ [accessed 13 August 2026]
5. Rubino, D., Abrahamsson, N., Davies, M., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes cannot be guaranteed. Wegovy is a prescription-only medicine licensed by the MHRA for chronic weight management in adults meeting specific BMI criteria.